4 results
To determine whether aleglitazar reduces cardiovasculair mortality and morbidity (defined as non-fatal myocardial infarction (MI) and non-fatal stroke) in patients with a recent ACS event and type 2 diabetes.
To evaluate the feasibility and usability of the adapted Lifestyle-integrated Functional Exercise Programme (aLiFE) and the enhanced LiFE (eLiFE) intervention, versus a control group, in a population of young old adults (61-70 years) at three sites…
To evaluate the feasibility and acceptability of the enhanced Lifestyle-integrated Functional Exercise Programme (eLiFE) intervention in a population of young old adults (60-70 years) at three sites: Stuttgart, Amsterdam, and Trondheim.
To determine the feasibility of umbilical PO for HR measurements after cord clamping in infants needing stabilization at birth and to compare this with standard PO on the right hand.